"They are aware of a company infringing their patents but it may currently not be worth fighting over, however they mentioned that if cost is not restrictive, they will defend."
See that's a pretty tricky situation aswell considering I'd assume one of the big pharmas key pieces of undertaking due dilligence was to ensure all the IP & patents are firmly locked down & protected, however the company certainly sounds on top of the game without concern & i guess if it was pressing on one of the key areas for a current partner then they would probably contribute to costs if "fighting" over it became essential.
PYC Price at posting:
4.3¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)